Xenon Pharmaceuticals (XENE) Tops Q3 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Xenon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 5, 2019 4:01 PM ESTIn Addition to Ongoing XEN1101 Phase 2b Clinical Trial in Adult Focal Epilepsy, Company Advances Epilepsy Programs and Anticipates Initiating Pediatric Clinical Trials in KCNQ2 (XEN496) and SCN8A (XEN901) Developmental and Epileptic Encephalopathies in 2020Â
XEN007 Phase 2 Proof-Of-Concept, Physician-Led Study Initiated in Pediatric Patients with  Treatment-Resistant Childhood Absence Epilepsy
Conference Call at 4:30 pm ET Today
BURNABY, British Columbia, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:... More
